Should I buy Lilly (Eli) (LLY) stock or is it too late?

Lilly (Eli) · Health Care · price $1,176

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Jefferies — 72% of its targets hit on this sector (380 calls tested). It aims for $1,350 (+15 %), call made on June 10, 2026, maturing on June 10, 2027 (79 d ago).

The 11 reliable analysts $1,350+15 %

The 5 other firms $1,400+19 %

How to read it: the 11 reliable firms are not filtered by optimism — 11 aim above the price, 0 below, hence their $1,350 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Lilly (Eli)

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
UBS	100 %	+50.2 %	6	$1,425 +21%
Morgan Stanley	90 %	+50.1 %	41	$1,347 +15%
Wells Fargo	91 %	+45.5 %	11	$1,330 +13%
Guggenheim	78 %	+40.4 %	9	$1,273 +8%
JP Morgan	88 %	+38.3 %	17	$1,400 +19%
Truist Securities	86 %	+37.0 %	14	$1,376 +17%
Citigroup	91 %	+32.2 %	11	$1,600 +36%
Cantor Fitzgerald	66 %	+27.0 %	47	$1,410 +20%

In short — Should you invest in Lilly (Eli)? Is it too late, still worth it? Analysts are overwhelmingly positive (94% buy, median target $1,363, i.e. +16%). But the valuation is stretched (P/E ~40). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

94% of analysts rate it a buy (Buy consensus, 16 ratings) — a sign of market conviction.
Median price target $1,363, i.e. +16% from the current price ($1,176).
10 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

Even the most reliable firm on LLY, HSBC (100% hit rate, 2 scored calls), only targets $850 (call made on March 17, 2026, maturing on March 17, 2027) (-28%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 16 ratings, 1 is a sell.
High valuation (P/E ~40): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on LLY

Median target $1,363 (+16%) · 16 ratings · Buy consensus

Strong Buy00%

Buy1594%

Hold00%

Sell16%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Lilly (Eli) now?

We won't decide for you. The facts: 94% of analysts rate it a buy, median target $1,363 (+16%), and HSBC (most reliable on LLY, 100%) targets $850. Weigh that against valuation (P/E ~40). This is not personalized advice.

Is it too late to invest in Lilly (Eli)?

Not according to analysts: the median target ($1,363) is still +16% above the current price ($1,176) (most reliable on LLY: HSBC, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Lilly (Eli) still worth investing in?

It depends on the gap between the price ($1,176) and its estimated value: analysts target $1,363 on median (+16%), with 94% buys (most reliable on LLY: HSBC, 100%). Cross-check with their real reliability on LLY and the cautions above. Information, not advice.

What's the main risk in buying LLY?

Even the most reliable firm on LLY, HSBC (100% hit rate, 2 scored calls), only targets $850 (call made on March 17, 2026, maturing on March 17, 2027) (-28%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Lilly (Eli) profile (consensus, analyst reliability, price target, performance).